EBS - SIGA Emergent extend gains as monkeypox cases rise

As monkeypox cases continue to rise worldwide, a group of companies focused on therapeutics and vaccines targeted at a close relative of the virus has extended their recent gains in the pre-market on Monday. Monkeypox is a rare viral disease most common in remote parts of Central and West Africa and therapeutics and vaccines against smallpox offer cross protection against the disease After making record gains last week, smallpox drugmakers, SIGA Technologies (NASDAQ:SIGA) and Chimerix (CMRX) have added ~13% and ~8% respectively, on above average volume. Emergent Biosolutions (EBS) which offers a smallpox vaccine is trading ~10% higher. Following the reports of 80 cases on Friday, the World Health Organization (WHO) reported 92 global monkeypox cases in 12 countries as of Saturday. Another 28 cases are under investigation. The U.S. confirmed its first monkeypox infection last Wednesday with another two suspected cases. Meanwhile, Belgium introduced a mandatory 21-day quarantine for monkeypox patients on

For further details see:

SIGA, Emergent extend gains as monkeypox cases rise